| Steven A Thau, MD | |
|
1505 Post Rd E Ste 100, Westport, CT 06880-5512 | |
| (203) 221-3370 | |
| (203) 221-3380 |
| Full Name | Steven A Thau |
|---|---|
| Gender | Male |
| Speciality | Pulmonary Disease |
| Experience | 30 Years |
| Location | 1505 Post Rd E Ste 100, Westport, Connecticut |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1750312955 | NPI | - | NPPES |
| 001387168 | Medicaid | CT |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RP1001X | Internal Medicine - Pulmonary Disease | 288762 (New York) | Secondary |
| 207RP1001X | Internal Medicine - Pulmonary Disease | 038716 (Connecticut) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St. Vincent's Medical Center | Bridgeport, CT | Hospital |
| Stamford Hospital | Stamford, CT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Hartford Healthcare Medical Group Specialists Pllc | 3173866241 | 1138 |
News Archive
Genetic specialists at Dana-Farber/Children's Hospital Cancer Center (DF/CHCC) are recommending that children being treated for sarcoma should be offered genetic counseling for Li-Fraumeni syndrome, a rare condition that greatly raises a person's risk of developing additional cancers.
Acacia Pharma announces positive Phase 3 results with APD421 for the management of post-operative nausea & vomiting (PONV). The data generated demonstrated a statistically significant reduction in the incidence of PONV with APD421 compared to placebo in adult surgical patients at moderate to high risk of suffering PONV (PONV is defined as any episode of emesis or use of antiemetic rescue medication in the first 24 hours after surgery).
Decision Resources, Inc., a research and advisory firms focusing on pharmaceutical and health care issues, finds that restrictions by health insurers and government health authorities to control expenses may hurt the malignant melanoma drug market.
Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration (FDA) has granted tentative approval for the Company's Abbreviated New Drug Application (ANDA) to market its generic version of Novartis' breast cancer treatment Femara® (letrozole) Tablets, 2.5 mg. Final approval of Teva's Letrozole Tablets is expected upon expiry of patent protection for the brand product in June 2011.
People living with or beyond cancer are more likely to die from stroke than the general public, according to new Penn State research, and certain types of cancer may boost the risk even more.
› Verified 2 days ago
| Entity Name | Hartford Healthcare Medical Group Specialists Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023584216 PECOS PAC ID: 3173866241 Enrollment ID: O20190514001441 |
News Archive
Genetic specialists at Dana-Farber/Children's Hospital Cancer Center (DF/CHCC) are recommending that children being treated for sarcoma should be offered genetic counseling for Li-Fraumeni syndrome, a rare condition that greatly raises a person's risk of developing additional cancers.
Acacia Pharma announces positive Phase 3 results with APD421 for the management of post-operative nausea & vomiting (PONV). The data generated demonstrated a statistically significant reduction in the incidence of PONV with APD421 compared to placebo in adult surgical patients at moderate to high risk of suffering PONV (PONV is defined as any episode of emesis or use of antiemetic rescue medication in the first 24 hours after surgery).
Decision Resources, Inc., a research and advisory firms focusing on pharmaceutical and health care issues, finds that restrictions by health insurers and government health authorities to control expenses may hurt the malignant melanoma drug market.
Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration (FDA) has granted tentative approval for the Company's Abbreviated New Drug Application (ANDA) to market its generic version of Novartis' breast cancer treatment Femara® (letrozole) Tablets, 2.5 mg. Final approval of Teva's Letrozole Tablets is expected upon expiry of patent protection for the brand product in June 2011.
People living with or beyond cancer are more likely to die from stroke than the general public, according to new Penn State research, and certain types of cancer may boost the risk even more.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Steven A Thau, MD 1505 Post Rd E Ste 101, Westport, CT 06880-5512 Ph: (203) 221-3370 | Steven A Thau, MD 1505 Post Rd E Ste 100, Westport, CT 06880-5512 Ph: (203) 221-3370 |
News Archive
Genetic specialists at Dana-Farber/Children's Hospital Cancer Center (DF/CHCC) are recommending that children being treated for sarcoma should be offered genetic counseling for Li-Fraumeni syndrome, a rare condition that greatly raises a person's risk of developing additional cancers.
Acacia Pharma announces positive Phase 3 results with APD421 for the management of post-operative nausea & vomiting (PONV). The data generated demonstrated a statistically significant reduction in the incidence of PONV with APD421 compared to placebo in adult surgical patients at moderate to high risk of suffering PONV (PONV is defined as any episode of emesis or use of antiemetic rescue medication in the first 24 hours after surgery).
Decision Resources, Inc., a research and advisory firms focusing on pharmaceutical and health care issues, finds that restrictions by health insurers and government health authorities to control expenses may hurt the malignant melanoma drug market.
Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration (FDA) has granted tentative approval for the Company's Abbreviated New Drug Application (ANDA) to market its generic version of Novartis' breast cancer treatment Femara® (letrozole) Tablets, 2.5 mg. Final approval of Teva's Letrozole Tablets is expected upon expiry of patent protection for the brand product in June 2011.
People living with or beyond cancer are more likely to die from stroke than the general public, according to new Penn State research, and certain types of cancer may boost the risk even more.
› Verified 2 days ago
Jay A Horn, M.D. Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 333 Post Rd W, Westport, CT 06880 Phone: 203-226-0731 | |
Dr. Boris V Sheynberg, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 32 Imperial Ave, Westport, CT 06880 Phone: 203-226-1760 Fax: 203-221-8291 | |
Dr. Steven W Ryder, M.D. Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 4 Ambler Rd W, Westport, CT 06880 Phone: 203-695-7933 | |
Dr. Samuel Frumkin, M.D. Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 162 Kings Hwy N, Westport, CT 06880 Phone: 203-226-0731 Fax: 203-226-1792 | |
Dr. Robban Ariel Sica, M.D. Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: C/o West Port Integrative Medicine, Llc Suite 100, 1 Turkey Hill Road South, Westport, CT 06880 Phone: 203-799-7733 Fax: 203-987-4853 | |
Deborah A. Mayer, M.D. Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 131 Kings Hwy N Ste 2, Westport, CT 06880 Phone: 203-557-8347 Fax: 203-557-8349 | |
Cristina Roxana Ionescu, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 333 Post Rd W, Westport, CT 06880 Phone: 203-226-0731 Fax: 203-226-1792 |